Abstract |
Aromatase inhibitor (AI) therapy is highly efficacious in the treatment of estrogen receptor-positive breast cancer; however, in a subset of patients AI use is discontinued due to drug-induced musculoskeletal adverse events (MS-AE). Several studies have investigated the role of germline single nucleotide polymorphisms (SNPs) on patients' risk of MS-AEs; however, no associations have yet to be validated for translation into clinical practice. This study attempted to replicate SNPs in RANKL ( rs7984870 ) and OPG ( rs2073618 ) on the risk of AI-induced MS-AEs and screen for secondary associations with MS-AE-related treatment discontinuation and serum and urine markers of bone health. Previously reported associations were not replicated with our primary hypothesis, change in MS-AE from baseline to 3 mo; however, patients homozygous for the G allele of rs7984870 in RANKL had lower risk of MS-AE-associated treatment discontinuation in analyses of secondary phenotypes without statistical correction.
|
Authors | Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, James M Rae, Daniel L Hertz |
Journal | Physiological genomics
(Physiol Genomics)
Vol. 50
Issue 2
Pg. 98-99
(02 01 2018)
ISSN: 1531-2267 [Electronic] United States |
PMID | 29212847
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aromatase Inhibitors
- Osteoprotegerin
- RANK Ligand
|
Topics |
- Adult
- Aged
- Aromatase Inhibitors
(therapeutic use)
- Breast Neoplasms
(drug therapy, genetics)
- Female
- Genetic Predisposition to Disease
(genetics)
- Humans
- Middle Aged
- Osteoprotegerin
(genetics)
- Polymorphism, Single Nucleotide
(genetics)
- Prospective Studies
- RANK Ligand
(genetics)
|